ImmunityBio (IBRX) Non-Current Debt (2015 - 2026)
ImmunityBio (IBRX) posted quarterly Non-Current Debt of $404.3 million for Q1 2026, up 36.46% year-over-year from $296.3 million in Q1 2025, and up 24.55% quarter-over-quarter from $324.6 million in Q4 2025.
ImmunityBio (IBRX) Non-Current Debt (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Non-Current Debt for 8 consecutive years, with $404.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 36.46% year-over-year to $404.3 million; the TTM figure through Mar 2026 stood at $404.3 million (up 36.46% YoY), while the FY2025 annual figure was $324.6 million, up 14.14% from the prior year.
- Non-Current Debt improved to $404.3 million in Q1 2026 per IBRX's latest filing, from $324.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $480.0 million in Q3 2023 and bottomed at $108.8 million in Q2 2024.
- Historically, Non-Current Debt has averaged $279.5 million across 5 years, with a median of $307.0 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Debt slumped 76.85% — and 2025, when it surged 184.45%.
- ImmunityBio's Non-Current Debt stood at $373.3 million in 2022, then sank by 58.37% to $155.4 million in 2023, then soared by 83.0% to $284.4 million in 2024, then rose by 14.14% to $324.6 million in 2025, then advanced by 24.55% to $404.3 million in 2026.
- Business Quant data shows IBRX's Non-Current Debt at $404.3 million in Q1 2026, $324.6 million in Q4 2025, and $316.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 415.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 415.09 Mn |
| Mar 31, 2026 | 404.30 Mn |
| Dec 31, 2025 | 324.62 Mn |
| Sep 30, 2025 | 316.15 Mn |
| Jun 30, 2025 | 307.05 Mn |
| Mar 31, 2025 | 296.29 Mn |
| Dec 31, 2024 | 284.40 Mn |
| Sep 30, 2024 | 111.14 Mn |
| Jun 30, 2024 | 108.81 Mn |
| Mar 31, 2024 | 163.42 Mn |
| Dec 31, 2023 | 155.42 Mn |
| Sep 30, 2023 | 480.02 Mn |
| Mar 31, 2023 | 245.64 Mn |
| Sep 30, 2022 | 373.29 Mn |
| Jun 30, 2022 | 312.54 Mn |
| Mar 31, 2022 | 309.43 Mn |
| Sep 30, 2021 | 303.24 Mn |
| Jun 30, 2021 | 300.25 Mn |
| Mar 31, 2021 | 297.29 Mn |
| Dec 31, 2020 | 254.35 Mn |